Latest From Pfenex Inc.
Hailing the past year as a "transformational period" in which "we moved towards being a business with an FDA-approved product nearing commercialization," Pfenex ended 2019 in profit and with cash in the bank, as it eyes the potential for a monopoly in the follow-on teriparatide market.
Two familiar industry figures have bolstered Amneal’s board, while Latvia’s Olanfarm has turned to a Sanofi executive for external expertise. Meanwhile, both Taro and Pfenex are recruiting CFOs.
Israel’s Kamada has struck a licensing deal with Alvotech that gives it rights to several of the firm’s biosimilars in its domestic market. The first launch, of the teriparatide biosimilar co-developed with Pfenex, is planned for 2022.
Pfenex believes it and commercial partner Alvogen could enjoy an extended period as the only direct competitor to Eli Lilly’s Forteo teriparatide reference brand in the US.
- Drug Discovery Tools
- Large Molecule
- Synthesis Technologies, Production Processes
- Generic Drugs
- Research, Analytical Equipment & Supplies
- Therapeutic Areas
- North America
- Parent & Subsidiaries
- Pfenex Inc.
- Senior Management
Evert (Eef) Schimmelpennink, Pres. & CEO
Susan Knudson, CFO
Patrick K Lucy, CBO
Hubert C Chen, MD, CMO & CSO
- Contact Info
Phone: (858) 352-4400
10790 Roselle St.
San Diego, CA 92121
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.